Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.

Biochemical pharmacology - 1 Feb 2021

Alvarado-Cruz Isabel, Mahmoud Mariam, Khan Mohammed, Zhao Shilin, Oeck Sebastian, Meas Rithy, Clairmont Kaylyn, Quintana Victoria, Zhu Ying, Porciuncula Angelo, Wyatt Hailey, Ma Shuangge, Shyr Yu, Kong Yong, LoRusso Patricia M, Laverty Daniel, Nagel Zachary D, Schalper Kurt A, Krauthammer Michael, Sweasy Joann B

Abstract excerpt

Poly-ADP-ribose polymerase (PARP) inhibitors are active against cells and tumors with defects in homology-directed repair as a result of synthetic lethality. PARP inhibitors (PARPi) have been suggested to act by either catalytic inhibition or by PARP localization in chromatin. In this study, we treat BRCA1 mutant cells derived from a patient with triple negative breast cancer and control cells for three weeks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Cytokines

Share to Gene Expression Regulation, Neoplastic

Share to Immunologic Factors

Share to Inflammation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 33285109
DOI: 10.1016/j.bcp.2020.114359
PMCID: PMC8668236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.PMID 33285109Read ↗

Chromatin-Bound PARP1 Correlates with Upregulation of Inflammatory Genes in Response to Long-Term Treatment with VeliparibSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsSemantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read ↗

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage responseSemantic proximity Read ↗

PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.Semantic proximity Read ↗

Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer DiseasesSemantic proximity Read ↗

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerSemantic proximity Read ↗

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic LethalitySemantic proximity Read ↗

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitorsSemantic proximity Read ↗

Distinct roles for PARP-1 and PARP-2 in c-Myc–driven B-cell lymphoma in miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.